1. Academic Validation
  2. 3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation

3',5'-Cyclic diguanylic acid (c-di-GMP) inhibits basal and growth factor-stimulated human colon cancer cell proliferation

  • Biochem Biophys Res Commun. 2005 Apr 1;329(1):40-5. doi: 10.1016/j.bbrc.2005.01.093.
David K R Karaolis 1 Kunrong Cheng Michael Lipsky Ahmed Elnabawi Jennifer Catalano Mamoru Hyodo Yoshihiro Hayakawa Jean-Pierre Raufman
Affiliations

Affiliation

  • 1 Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. karaolis@umaryland.edu
Abstract

The novel cyclic dinucleotide, 3',5'-cyclic diguanylic acid, cGpGp (c-di-GMP), is a naturally occurring small molecule that regulates important signaling mechanisms in prokaryotes. Recently, we showed that c-di-GMP has "drug-like" properties and that c-di-GMP treatment might be a useful antimicrobial approach to attenuate the virulence and pathogenesis of Staphylococcus aureus and prevent or treat Infection. In the present communication, we report that c-di-GMP (50 microM) has striking properties regarding inhibition of Cancer cell proliferation in vitro. c-di-GMP inhibits both basal and growth factor (acetylcholine and epidermal growth factor)-induced cell proliferation of human colon Cancer (H508) cells. Toxicity studies revealed that exposure of normal rat kidney cells and human neuroblastoma cells to c-di-GMP at biologically relevant doses showed no lethal cytotoxicity. Cyclic dinucleotides, such as c-di-GMP, represent an attractive and novel "drug-platform technology" that can be used not only to develop new antimicrobial agents, but also to develop novel therapeutic agents to prevent or treat Cancer.

Figures
Products